When you work with more than one FDA center, even small misunderstandings about who does what or which rules matter can waste time and create risk. This workshop reframes the map of FDA decision-making, shows how to prepare submissions and meetings to what is binding, and sets an ethics compass for communications and documentation that hold up under scrutiny.

Topics of discussion include:

• Understanding the new Human Foods Program and Office of Cosmetics and Colors
• Mapping CDER, CBER, and CDRH roles and locating OPDP, OII, and OSE across the lifecycle
• Structuring IND and IDE pathways and sequencing Type A, B, and C meetings to keep momentum
• Distinguishing rules from guidance and framing comments and appeals that move the record
• Managing inspections, 483s, and EIRs and coordinating FDA, DOJ, and state actions
• Linking labeling to promotion, REMS, and pharmacovigilance to prevent downstream missteps
• Documenting decisions and building an administrative record that withstands challenge
• Upholding ethics on candor, conflicts, and confidentiality and clarifying communication boundaries